New pill targets Hard-to-Treat cancer mutation in early trial

NCT ID NCT05009329

Ongoing Disease control Sponsor: Allist Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests an experimental oral drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific mutation in the KRAS gene (G12C). The trial aims to find the best dose and check if the drug is safe and can shrink tumors. About 315 adults whose cancer has not responded to standard treatments are participating.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JAB-21822 (glecirasib), an oral drug that targets a specific cancer-driving mutation (KRAS G12C)
What this could lead to: If successful, this could provide a new treatment option for people with advanced cancers that have a KRAS G12C mutation, especially when other treatments have stopped working.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC SOLID TUMOR

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.